Document Detail


Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering of low-density lipoprotein.
MedLine Citation:
PMID:  16784936     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This editorial outlines the data supporting aggressive lipid goals and options for treating low-density lipoprotein (LDL) cholesterol to a range of approximately 30 to 70 mg/dl. The physiologically normal cholesterol range is approximately 30 to 70 mg/dl for native hunter-gatherers, healthy human neonates, free-living primates, and virtually all wild mammals. Randomized statin trials in patients with recent acute coronary syndromes and stable coronary artery disease have demonstrated that cardiovascular events are reduced and cardiovascular survival optimized when LDL cholesterol is reduced to <70 mg/dl. Secondary prevention trials have shown a decrease in all-cause mortality in proportion to the magnitude of LDL cholesterol reduction. An original analysis of available data shows that the ability of a lipid-lowering therapy to reduce the C-reactive protein level is closely correlated with its efficacy in LDL cholesterol reduction. Randomized trial data have shown no relation between either percentage LDL cholesterol decrease or final LDL cholesterol level achieved and the risk for myopathy or hepatic transaminase elevations associated with statins. Therefore, intensive LDL cholesterol reduction to levels of 30 to 70 mg/dl should be pursued in subjects with or at high risk for coronary artery disease.
Authors:
James H O'Keefe; Loren Cordain; Philip G Jones; Hussam Abuissa
Related Documents :
17907956 - The road to load: late-onset alzheimer's disease and a possible way to block it.
20413736 - Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison o...
2667936 - Probucol. a reappraisal of its pharmacological properties and therapeutic use in hyperc...
17393216 - Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in stati...
17949356 - Oscillations in total body fat content through life: an evolutionary perspective.
23939686 - 'mediterranean' dietary pattern for the primary prevention of cardiovascular disease.
Publication Detail:
Type:  Editorial     Date:  2006-05-09
Journal Detail:
Title:  The American journal of cardiology     Volume:  98     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-08-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  135-9     Citation Subset:  AIM; IM    
Affiliation:
Mid America Heart Institute, Kansas City, Missouri, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / blood
C-Reactive Protein / metabolism*
Cholesterol, LDL / blood*
Coronary Artery Disease / blood*,  diagnosis*,  mortality,  prevention & control
Humans
Inflammation / complications
Prognosis
Randomized Controlled Trials as Topic
Risk Factors
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Cholesterol, LDL; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What the statin trials have taught us.
Next Document:  Pseudomembranous colitis revisited: spectrum of imaging findings.